While it was recently reported that low-dose metformin activates lysosomal AMPK via the PEN2-ATP6AP1 axis, thereby reducing hepatic steatosis in an HFD model (57), we did not observe indicators that AMPK was activated at the study endpoint (Supplemental Fig. S1C). This evidence concerns the gene PRKAA1 and fatty liver disease.